Skip to main content
. 2013 Jul 22;110(32):13174–13179. doi: 10.1073/pnas.1312065110

Fig. 2.

Fig. 2.

PXR activation attenuates EC apoptosis. HUVECs were pretreated by rifampicin (20 μM) or vehicle (DMSO) for 24 h before exposed to doxorubicin (A) (5 μM, 24 h) or staurosporine (B) (500 nM, 6 h). Apoptosis was assessed by using flow cytometry for annexin V-FITC. (C) Intracellular level of doxorubicin was measured by using flow cytometry for fluorescence intensity in HUVECs pretreated with rifampicin (with or without SFN) in the presence or absence of PSC833 before exposure to doxorubicin. (D) Caspase 3 cleavage was detected with Western blotting. (E) HUVECs were treated with LSS or kept static for 12 h before exposure to doxorubicin for 12 h or staurosporine for 6 h. (F) HUVECs were transfected with PXR or control siRNA for 48 h and exposed to LSS or kept static for another 12 h. Apoptosis was detected after exposure to doxorubicin or staurosporine. Data shown are as mean ± SEM of three independent experiments. *P < 0.05 vs. control. #P < 0.05 vs. DMSO (A and B) or Rif (C).